Association between Non Alcoholic Fatty Liver Disease and Coronary Artery Disease.
DOI:
https://doi.org/10.48165/nad8tj04Abstract
Background: To study the association of Non Alcoholic Fatty Liver Disease in patients of Coronary Artery Disease. Subjects and Methods: 100 patients of established CAD admitted were included in the study. Patients were screened for NAFLD with USG. 2 groups were made: CAD with NAFLD & CAD without NAFLD and comorbidities were identified and evaluated for Risk Factors and Correlation was identified. Result: Majority of study subjects (79%) were males and 21% were females. Highest proportion of subjects (29%) were in 51-60 years of age and lowest (9%) in above 70 years of age. Chest pain was the commonest presenting symptom preceding breathlessness and sweating. In the fatty liver group, a high proportion of subjects had history of Type-II DM (31% vs 4%) and Hypertension (18% vs 11%) in comparison to normal liver group. The mean BMI of study participants in the present study was 29.5 kg/m2. In fatty liver group, higher proportion of subjects had fasting blood glucose levels > 126 (66.7%) than the non-fatty liver subjects (3.8%). higher proportion of subjects had total cholesterol levels higher than 200 (14.6%) than the non-fatty liver subjects (1.9%). In group with non-fatty liver, greater proportion of subjects had LDL levels higher than 100 (40.4%) than the fatty liver group (33.3%). it was found that 37.5% subjects had mild grade of NAFLD whereas 43.8% had moderate grade and 18.7% had severe grade of NAFLD. Conclusion: There is a significant relationship between NAFLD and an elevated CVD risk in those with or without Metabolic Syndrome.
References
1. Ahmed MH, Barakat S, Almobarak AO. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Has the Time Come for Cardiologists to Be Hepatologists? J Obesity. 2012;2012:483135. Available from: https://doi.org/10.1155/ 2012/483135.
2. Lerchbaum E, Pilz S, Grammer TB, Boehm BO, Stojakovic T, Obermayer-Pietsch B. The fatty liver index is associated with increased mortality in subjects referred to coronary angiography. Nutr Metab Cardiovasc Dis. 2013;23(12):1231– 1238. Available from: https://doi.org/10.1016/j.numecd.2013. 02.004.
3. Zafar KS, Wafai NA, Haque SF. Correlation of non-alcoholic fatty liver disease in patients of coronary artery disease. Int J Res Med Sci. 2016;4(3):739–742. Available from: https: //dx.doi.org/10.18203/2320-6012.ijrms20160510.
4. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191(2):235–240. Available from: https://doi.org/10. 1016/j.atherosclerosis.2006.08.021.
5. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol. 2016;65(3):589–600. Available from: https://doi.org/10.1016/j.jhep.2016.05.013.
6. Wong VS, Wong GH, Yeung JL, Fung CK, Chan JL, Chang ZY. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. Hepatology. 2016;63(3):754–763. Available from: https://doi.org/10.1002/hep.28253.
7. Ma J, Hwang SJ, Pedley A, Massaro JM, Hoffmann U, Chung RT. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol. 2017;66(2):390– 397. Available from: https://doi.org/10.1016/j.jhep.2016.09. 022.
8. Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Association of non alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis. Sci Rep. 2016;6:33386.
9. Wild SH, Walker JJ, Morling JR, Mcallister DA, Colhoun HM, Farran B, et al. Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission. Diabetes Care. 2018;41(2):341–347. Available from: https: //doi.org/10.2337/dc17-1590.
10. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357. Available from: https://doi. org/10.1002/hep.29367.
11. Mullish BH, Forlano R, Manousou P, Mikhailidis DP. Non alcoholic fatty liver disease and cardiovascular risk: an update. Expert Rev Gastroenterol Hepatol. 2018;12(12):1175– 1182. Available from: https://doi.org/10.1080/17474124.2018. 1533117.
12. Wong CR, Lim JK. The Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease Outcomes. Clin Liver Dis (Hoboken). 2018;12(2):39–44. Available from: https://dx.doi.org/10.1002/cld.721.
13. Chan WK, Tan AB, Vethakkan SR, Tah PC, Vijayananthan A, Goh KL. Ultrasonography-diagnosed non-alcoholic fatty liver disease is not associated with prevalent ischemic heart disease among diabetics in a multiracial Asian hospital clinic
population. Clin Res Hepatol Gastroenterol. 2014;38(3):284– 91. Available from: https://doi.org/10.1016/j.clinre.2014.02. 009.
14. Montemezzo M, Alturki A, Stahlschmidt F, Olandoski M, Tafarel R, Precoma J, et al. Nonalcoholic Fatty Liver Disease and Coronary Artery Disease: Big Brothers in Patients with Acute Coronary Syndrome. Sci World J. 2020;2020:1–5. Available from: https://doi.org/10.1155/2020/8489238.
